| Expert consensus recommendations for the performance of peripheral nerve blocks for headaches–a narrative review A Blumenfeld, A Ashkenazi, U Napchan, SD Bender, BC Klein, R Berliner, ... Headache: The Journal of Head and Face Pain 53 (3), 437-446, 2013 | 248 | 2013 |
| COVID-19 is catalyzing the adoption of teleneurology BC Klein, NA Busis Neurology 94 (21), 903-904, 2020 | 168 | 2020 |
| Migraine care in the era of COVID‐19: Clinical pearls and plea to insurers CL Szperka, J Ailani, R Barmherzig, BC Klein, MT Minen, ... Headache: The Journal of Head and Face Pain 60 (5), 833-842, 2020 | 124 | 2020 |
| Getting to the heart of the matter: Migraine, triptans, DHE, ditans, CGRP antibodies, first/second‐generation gepants, and cardiovascular risk PG Mathew, BC Klein Headache: The Journal of Head and Face Pain 59 (8), 1421-1426, 2019 | 41 | 2019 |
| Antiamyloid monoclonal antibody therapy for Alzheimer disease: emerging issues in neurology VK Ramanan, MJ Armstrong, P Choudhury, KA Coerver, RH Hamilton, ... Neurology 101 (19), 842-852, 2023 | 39 | 2023 |
| A retrospective analysis of triptan and dhe use for basilar and hemiplegic migraine PG Mathew, R Krel, B Buddhdev, H Ansari, SG Joshi, WD Spinner, ... Headache: The Journal of Head and Face Pain 56 (5), 841-848, 2016 | 35 | 2016 |
| Safety and tolerability results of atogepant for the preventive treatment of episodic migraine from a 40-week, open-label multicenter extension of the phase 3 ADVANCE trial BC Klein, R Miceli, L Severt, P McAllister, L Mechtler, J McVige, ... Cephalalgia 43 (1), 03331024221128250, 2023 | 18 | 2023 |
| 4TH, YOUNG WB, ROBERTSON CE, DODICK DW, SILBERSTEIN SD, ROBBINS MS. Expert consensus recommendations for the performance of peripheral nerve blocks for headaches–a narrative review A Blumenfeld, A Ashkenazi, U Napchan, SD Bender, BC Klein, R Berliner, ... Headache 53 (3), 437-46, 2013 | 10 | 2013 |
| An optional second dose of ubrogepant is effective in achieving 2-hour pain freedom in the acute treatment of migraine J Ailani, AM Blumenfeld, B Klein, M Finnegan, L Severt, C Liu, ... Headache 59, 98-98, 2019 | 6 | 2019 |
| Futures planning at the AAN: approach and initial outcome CE Jackson, LK Jones Jr, BC Klein, NR Rost, SM Benish, BT Levi, ... Neurology 96 (22), 1032-1040, 2021 | 5 | 2021 |
| Association of neurologist care with headache expenditures: a population-based, longitudinal analysis JP Ney, JJ Sico, BC Klein, B Magliocco, BC Callaghan, GJ Esper Cephalalgia 38 (12), 1876-1884, 2018 | 5 | 2018 |
| Characterizing prodrome (premonitory phase) in migraine: results from the PRODROME trial screening period TJ Schwedt, RB Lipton, PJ Goadsby, CC Chiang, BC Klein, C Hussar, ... Neurology: Clinical Practice 15 (1), e200359, 2025 | 4 | 2025 |
| Characterizing prodrome (premonitory phase) in migraine: results from the PRODROME Trial Screening Period (S41. 009) TJ Schwedt, RB Lipton, PJ Goadsby, CC Chiang, B Klein, C Liu, SY Yu, ... Neurology 100 (17_supplement_2), 1669, 2023 | 2 | 2023 |
| Evaluation of the long-term safety and tolerability of oral atogepant 60 mg once daily for preventive treatment of migraine: a phase 3, 40-week, multicenter extension to the … B Klein, R Miceli, L Severt, P McAllister, L Mechtler, J McVige, M Diamond, ... Neurology 98 (18_supplement), 1753, 2022 | 2 | 2022 |
| Safety and tolerability of ubrogepant for the acute treatment of migraine in participants taking atogepant for the preventive treatment of episodic migraine: Results from the … J Ailani, RB Lipton, AM Blumenfeld, L Mechtler, BC Klein, MY He, ... Headache: The Journal of Head and Face Pain, 2024 | 1 | 2024 |
| Early onset of efficacy with atogepant for the preventive treatment of chronic migraine: results from the PROGRESS trial J Ailani, U Reuter, C Graboski, BC Klein, SY Yu, K Nagy, H Guo, ... Cephalalgia 42 (1_ SUPPL), 32-33, 2022 | 1 | 2022 |
| Asking the right questions: The value of headache specialty care. BC Klein Headache 62 (4), 401-401, 2022 | 1 | 2022 |
| Safety and tolerability of ubrogepant within various demographic and clinical characteristic subgroups J Ailani, B Klein, LL Mechtler, B Plato, S Yu, L Severt, ... HEADACHE 60, 124-125, 2020 | 1 | 2020 |
| Rapiditié d’efficacité de l’atogépant pour le traitement préventif de la migraine chronique: résultats de l’étude PROGRESS J Ailani, U Reuter, C Graboski, BC Klein, G Demarquay, J Trugman Revue Neurologique 180, S32, 2024 | | 2024 |
| 2631 Early onset of efficacy with Atogepant for the preventive treatment of chronic migraine: results from the PROGRESS trial J Ailani, U Reuter, BC Klein, SY Yu, K Nagy, H Go, K Watts, J Trugman BMJ Neurology Open 5 (Suppl 1), 2024 | | 2024 |
Jessica AilaniProfessor of Clinical NeurologyVerified email at medstar.net
